ARS Pharmaceuticals (SPRY) Equity Average (2021 - 2025)
ARS Pharmaceuticals (SPRY) has disclosed Equity Average for 5 consecutive years, with $131.0 million as the latest value for Q4 2025.
- Quarterly Equity Average fell 42.79% to $131.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $131.0 million through Dec 2025, down 42.79% year-over-year, with the annual reading at $185.5 million for FY2025, 23.9% down from the prior year.
- Equity Average hit $131.0 million in Q4 2025 for ARS Pharmaceuticals, down from $170.0 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $359.1 million in Q2 2021 to a low of -$47.1 million in Q3 2022.
- Historically, Equity Average has averaged $182.9 million across 5 years, with a median of $219.6 million in 2024.
- Biggest five-year swings in Equity Average: plummeted 113.81% in 2022 and later skyrocketed 868.14% in 2023.
- Year by year, Equity Average stood at $150.4 million in 2021, then fell by 25.97% to $111.4 million in 2022, then skyrocketed by 110.14% to $234.0 million in 2023, then decreased by 2.19% to $228.9 million in 2024, then crashed by 42.79% to $131.0 million in 2025.
- Business Quant data shows Equity Average for SPRY at $131.0 million in Q4 2025, $170.0 million in Q3 2025, and $210.6 million in Q2 2025.